X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://telixpharma.com/news-views/telix-elects-to-withdraw-from-proposed-u-s-listing/
https://www.globenewswire.com/news-release/2024/06/05/2893759/0/en/Telix-Announces-Launch-of-Proposed-Initial-Public-Offering-in-the-United-States.html
https://www.globenewswire.com/news-release/2024/06/02/2891867/0/en/Telix-Completes-TLX250-CDx-Zircaix-BLA-Submission-for-Kidney-Cancer-Imaging.html
https://www.globenewswire.com/news-release/2024/05/30/2891221/0/en/Telix-Announces-Positive-rPFS-Data-from-ProstACT-SELECT-Trial-of-TLX591-rADC-Therapy-Candidate-in-Prostate-Cancer.html
https://www.prnewswire.com/news-releases/telix-announces-positive-rpfs-data-from-prostact-select-trial-of-tlx591-radc-therapy-candidate-in-prostate-cancer-302160145.html
https://www.globenewswire.com/news-release/2024/05/28/2888867/0/en/Telix-Submits-NDA-for-New-Prostate-Cancer-Imaging-Agent.html
https://www.globenewswire.com/news-release/2024/05/20/2885205/0/en/Telix-Completes-Proof-of-Concept-Study-of-TLX592-Targeted-Alpha-Therapy-in-Prostate-Cancer.html
https://www.prnewswire.com/news-releases/telix-completes-proof-of-concept-study-of-tlx592-targeted-alpha-therapy-in-prostate-cancer-302150652.html
https://www.renaissancecapital.com/IPO-Center/News/104755/Australian-radiopharmaceutical-biotech-Telix-Pharmaceuticals-files-for-a-$100-million-US-IPO
https://www.globenewswire.com/news-release/2024/04/17/2864263/0/en/Q1-2024-Revenue-and-Business-Update.html
Market Place
Share 
